AnPac Bio-Medical Science Co., Ltd. (ANPC) News

AnPac Bio-Medical Science Co., Ltd. (ANPC): $0.30

0.03 (+9.64%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ANPC to Watchlist
Sign Up

Industry: Biotech


Ranked

of 446

in industry

Filter ANPC News Items

ANPC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ANPC News Highlights

  • ANPC's 30 day story count now stands at 2.
  • Over the past 3 days, the trend for ANPC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • BIO, DRUG and FGI are the most mentioned tickers in articles about ANPC.

Latest ANPC News From Around the Web

Below are the latest news stories about AnPac Bio-Medical Science Co Ltd that investors may wish to consider to help them evaluate ANPC as an investment opportunity.

AnPac Bio Files CDA Device for Breakthrough Medical Device Designation Request with the FDA

PHILADELPHIA, Feb. 03, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced today that it has filed for a Breakthrough device designation request for its cancer differentiation analysis (CDA) technology based medical device with the Food and Drug Administration (FDA) on February 1, 2022. AnPac Bio’s novel CDA techno

Yahoo | February 3, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, trader!

William White on InvestorPlace | January 31, 2022

Leading US Market Analysis and Research Firm Ranked AnPac Bio Globally Number One in Multi-Cancer Screening and Detection Test Volume

PHILADELPHIA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced today that Frost & Sullivan Company (“Sullivan”), a leading and well-known US market analysis and research firm has ranked AnPac Bio globally as number one in worldwide multiple cancer screening and detection volume in a recent research repo

Yahoo | January 25, 2022

AnPac Bio receives Nasdaq notification regarding minimum market value (NASDAQ:ANPC)

AnPac Bio-Medical Science (ANPC) has received a written notification from the Nasdaq that the Co

Seeking Alpha | January 24, 2022

G Medical, Reviva top healthcare gainers; OPKO Health, AnPac Bio-Medical among losers

G Medical Innovations (GMVD) +18%. Reviva Pharmaceuticals (RVPH) +14%. OPKO Health (OPK) -20%. AnPac Bio-Medical Science (ANPC) -18%.

Seeking Alpha | January 24, 2022

AnPac Bio Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

PHILADELPHIA, Jan. 24, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, announced today that it has received a written notification (the "Notification Letter") from the Nasdaq Stock Market LLC (“Nasdaq”) dated January 19, 2022 indicating that the Company is not in compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) set forth in the Nasdaq

Yahoo | January 24, 2022

AnPac Bio Class III Medical Device Passes Extensive NMPA Registration Tests and Will Start Clinical Trial in Q1, 2022

PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a US and China-based biotechnology company focused on early cancer screening and detection, announced today that on December 30, 2021, the Company’s Class III medical device for lung cancer auxiliary diagnosis has completed and passed stringent and rigorous registration tests at the testing laboratory designated by the National Medical Products Administration (NMPA), C

Yahoo | January 4, 2022

Technical Paper on AnPac Bio Novel CDA Cancer Detection Technology Published by Peer-Reviewed International Medical Journal

PHILADELPHIA, Dec. 10, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its joint technical paper on novel Cancer Differentiation Analysis (CDA) Technology for multi-cancer screening with multiple leading medical institutions was accepted and published online on November 30, 2021 by the Expert Review of Molecular Diagnostics, a peer-reviewed int

Yahoo | December 10, 2021

AnPac Bio-Medical Science reports 9M results

No summary available.

Seeking Alpha | November 26, 2021

AnPac Bio Reports Nine Months Ended September 30, 2021, Same Period Achieved Record Revenue Increased By 55.3% While Non-GAAP Net Loss Reduced by 6.8%

PHILADELPHIA, Nov. 26, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its unaudited financial results for the nine months ended September 30, 2021. The Company's financial statements and related financial information for the quarter ended September 30, 2021 are unaudited and have not been reviewed by the Company's independent registered accoun

Yahoo | November 26, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6246 seconds.